The 5' splice site of a pre-mRNA is recognized by U1 small nuclear ribonucleoprotein particles (snRNP) through base pairing with the 5' end of U1 small nuclear RNA (snRNA). Single-base substitutions within a 9-nucleotide 5'-splice-site sequence can abolish or attenuate use ofthat site and, in higher eukaryotes, can also activate nearby "cryptic" 5' splice sites. Here we show that the effects of single-base substitutions within a 5' splice site can be completely or partially suppressed by cis mutations that improve the overall complementarity ofthe site to U1 snRNA. We further show that in the presence of the normal 5' splice site, a cryptic 5' splice site can be activated by increasing its complementarity to U1 snRNA. U1 snRNP binding experiments confirm that cryptic 5' splice sites are activated when their affinity for U1 snRNP approaches that of the authentic 5' splice site. Based upon these results, we propose a spliceosome competition model for 5'-splice-site selection and cryptic 5'-splice-site activation. We discuss our results with regard to the factors involved in 5'-splice-site recognition.
ABSTRACT
The 5' splice site of a pre-mRNA is recognized by U1 small nuclear ribonucleoprotein particles (snRNP) through base pairing with the 5' end of U1 small nuclear RNA (snRNA). Single-base substitutions within a 9-nucleotide 5'-splice-site sequence can abolish or attenuate use ofthat site and, in higher eukaryotes, can also activate nearby "cryptic" 5' splice sites. Here we show that the effects of single-base substitutions within a 5' splice site can be completely or partially suppressed by cis mutations that improve the overall complementarity ofthe site to U1 snRNA. We further show that in the presence of the normal 5' splice site, a cryptic 5' splice site can be activated by increasing its complementarity to U1 snRNA. U1 snRNP binding experiments confirm that cryptic 5' splice sites are activated when their affinity for U1 snRNP approaches that of the authentic 5' splice site. Based upon these results, we propose a spliceosome competition model for 5'-splice-site selection and cryptic 5'-splice-site activation. We discuss our results with regard to the factors involved in 5'-splice-site recognition.
During pre-mRNA splicing, intron sequences are removed from the original RNA transcript (for review, see refs. [1] [2] [3] [4] . Three sequence elements that direct this RNA processing have been identified: the two sequence elements at the intron borders and the branch site upstream of the 3' splice site. The 5' splice site is a 9-nucleotide (nt) sequence. The consensus, 5'-CAG/GUAAGU-3', is complementary to the first 9 nt of the 5' end of U1 small nuclear RNA (snRNA) and base pairing of these two RNAs is a necessary step in pre-mRNA splicing (5). Natural 5' splice sites match the consensus to various extents, the vast majority deviating at two or three positions (6) (7) (8) . The most invariant positions are the almost universal GU dinucleotide at the cleavage site and the guanosine at position +5, which is present in 85% of the sequences analyzed.
Splicing occurs in a large complex, the spliceosome, which is composed of U1, U2, U5, and U4/6 small nuclear ribonucleoprotein particles (snRNP) and multiple proteins (for review, see refs. 1-4). It is believed that during spliceosome assembly the splice sites are selected. An initial step in assembly is binding of Ul snRNP to the 5' splice site (9-13). The Ul snRNP binding reaction does not require ATP and can occur on RNA substrates that contain only a 5' splice site (11) . Binding of U2 snRNP to the branch site is another early event. This binding reaction requires ATP hydrolysis and can occur on substrates that lack the 5' splice site (9, 11, 14, 15) . Thus, in higher eukaryotes, the two halves of the intron appear to be independently assembled into partial complexes, which are then brought into proximity.
Human /3-globin thalassemia is a disease that results from a deficiency of 8-globin polypeptide. At the molecular level the basis of the disease is diverse (see ref. 16 and references within). One class of thalassemic lesions is single-base substitutions within the 5' splice site of the human f-globin first intron (IVSI). These mutations reduce or eliminate use of the authentic 5' splice site, while activating three "cryptic" 5' splice sites (Fig. lA) COS Cell Transfections. The Nco I-BamHI fragments of the above globin constructions were moved into the vector f3+-Ela (19) . Each DNA (10 ,ug) was transfected onto 60% confluent COS cells as a calcium phosphate precipitate. The medium was changed after 24 hr, and the cells were harvested 44 hr after transfection. Cytoplasmic RNA was harvested as described (20) . (17) . 1 and in vitro, the P1 mutation completely ina4 authentic 5' splice site, whereas the P5 mutation,, reduces its activity.
In the ,B-globin derivative 5'--+ C, the normal ,B-S' splice site is altered to be perfectly compleme snRNA (18) . The P1 and P5 mutations were intr the 5' -> C background, producing the 5' splice sites CAG/ AUAAGU (CP1) and CAG/GUAACU (CP5), respectively.
These derivatives thus contain a thalassemic point mutation within a 5' splice site that is otherwise perfectly complementary to Ul snRNA.
Uniformly labeled transcripts derived from CP1 and CP5 were spliced in vitro (Fig. 1B) (Fig. 1B) . The 5'-+ C and CPS mutants give rise to a single product, the size of which is identical to that produced from the wild-type substrate. Finally, the -38* site is active in vivo (Fig. 4) , as well as in vitro (Fig. 1B) . In vivo, however, the -38* site is used exclusively, whereas in vitro the activities of the normal and the -38* sites are comparable.
The major difference between the in vivo and in vitro data is with regard to the CP1 mutant. Whereas in vitro the cryptic sites in the CP1 substrate are completely suppressed, in vivo splicing occurs both to the altered CP1 site and to the cryptic sites. Thus the additional substitutions in CP1 have less of a compensatory effect in vivo than in vitro. Perhaps this reflects differences in U1 snRNP binding properties in vivo and in vitro. A second difference is that the G --A substitution results in a block to splicing after the first step in vitro (Fig. 1B) , whereas in vivo some accurately spliced mRNA is produced (Fig. 4) .
DISCUSSION
The results presented here indicate that the effects of these ,8-globin 5'-splice-site thalassemic mutations result from the overall decrease in the affinity of the mutant sites for Ul snRNP. In particular, the effects of these mutations are not due solely to the replacement of required nucleotides at critical positions. This conclusion complements that of Aebi et al. (21) who suggested that the precise position of 5' cleavage results from the overall ability of a 5' splice site to base pair with Ul snRNA.
We further conclude that cryptic 5' splice sites are activated if their ability to bind Ul snRNP becomes comparable to that of the authentic 5' splice site. This can result from two different types of mutations. (i) Single-base substitutions within the authentic 5' splice site may decrease the affinity for U1 snRNP to the same approximate level as that of the cryptic sites. (ii) A cryptic 5' splice site, such as the -38 site, can be activated by increasing its ability to base pair with U1 snRNA. In fact, increased complementarity of potential cryptic 5' splice sites may be the basis of some natural thalassemias (27, 28) . Fig. 5 presents a model for 5'-splice-site selection and cryptic 5'-splice-site activation that incorporates the results presented here within the framework of our current understanding of spliceosome assembly. During this process a partial complex that includes U2 snRNP is assembled at the branch-site/3'-splice-site region of the intron. This partial complex then interacts with Ul snRNP bound at the 5' splice site (for review, see refs. [1] [2] [3] [4] . Under standard in vitro splicing conditions, Ul snRNP is in excess (18 approximately equal strength can have a U1 snRNP molecule simultaneously bound to each site (18) . Therefore, when the affinity of a cryptic 5' splice site becomes comparable to that of the authentic site, the multiple bound U1 snRNPs can compete with one another for interaction with the single bound U2 snRNP and associated factors. In the wild-type pre-mRNA, the affinity of cryptic sites for U1 snRNP is significantly lower than that of the authentic site. Thus, the vast majority of pre-mRNA molecules contain a single U1 snRNP bound to the authentic site. Although no direct studies have shown that U1 snRNP is also in excess in vivo, the similarity of our in vitro and in vivo results is consistent with this idea.
Although U1 snRNP binding affinity is a critical aspect of 5'-splice-site selection, it is not the only criterion. Some high-affinity U1 snRNP binding sites can be bound by U1 snRNP and yet are inactive for splicing (18) . Thus, the context of a U1 snRNP binding site plays an important role in splice site selection. The cryptic sites are all close to the authentic 5' splice site and presumably within a permissive context. This permissive context can be easily disrupted, since a small (9 nt) insertion between the -16 cryptic site and the authentic 5' splice site abolishes all splicing in a P1 mutant (24) .
One explanation for context effects is that there are additional factors that bind at or near 5' splice sites and are involved in 5'-splice-site recognition and/or selection. The results presented here demonstrate that the identity of the nucleotide at highly invariant positions +1 and +5 has little effect on either the efficiency or the fidelity of splicing: in each instance the effects of these mutations can either be completely or partially suppressed by appropriate cis substitutions. These results raise the possibility that U1 snRNP is the only factor involved in 5'-splice-site recognition within a given context; it seems unlikely that these cis substitutions, designed to increase RNARNA base pairing with Ul snRNA, would also have compensatory effects for protein factors.
